+44 (0)1865 595230
0 Items

Hepatitis B

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.

A vaccine against hepatitis B has been available since 1982. The vaccine is 95% effective in preventing infection and the development of chronic disease and liver cancer due to hepatitis B.

 

We offer a large panel of monoclonal antibodies specific for Hepatitis B, suitable for R&D and immunoassay development.

Hepatitis B background

Hepatitis B virus (HBV) is a small, partially double-stranded DNA virus that belongs to the genus Orthohepadnaviruses of the Hepadnaviridae family of viruses. Currently, eight genotypes of HBV are recognised, designated A-H, with each genotype having a distinct geographical distribution. HBV is a retrovirus that replicates by reverse transcription of an RNA intermediate. HBV encodes seven proteins, recognised as preCore, core, pol, X(HBx), and envelope proteins L, M and S (Liang ,TJ).

First recognised in the 1940s as an infectious agent causing hepatitis, the HBV virus was eventually identified in the mid-1960’s when HBV particles were detected in a patient’s serum. The particles, initially referred to as Australia antigen, were subsequently found to be HBV envelope proteins L, S and M. Collectively these particles are now known as hepatitis B surface antigen (HBsAg) (Seeger, C).

HBV is a bloodborne virus that is transmitted through contact with infected blood or bodily fluids. HBV infection may occur through various routes including the sharing of needles for injecting drugs, the use of inadequately sterilised medical equipment infected with HBV and the transfusion of unscreened blood and blood products. In endemic areas, perinatal transmission of HBV from mother to child is common.

HBV infection causes liver disease which can vary from acute, or chronic hepatitis to cirrhosis of the liver and potentially hepatocellular carcinoma. The incubation of HBV infection can vary from 1 – 6 months. During the period of acute infection, most individuals remain asymptomatic. However, some patients develop acute illness presenting with clinical symptoms that include jaundice, nausea, vomiting, abdominal pain and extreme fatigue. Acute liver failure may occur in 1% of patients, which can be fatal. HBV infected patients may also develop chronic lifelong disease, which can progress to cirrhosis or hepatocellular carcinoma in 20-30% of adult cases (WHO).
The asymptomatic nature of HBV infection, and the similarity of clinical symptoms to other types of hepatitis virus infection makes clinical diagnosis difficult. Therefore, laboratory diagnosis is undertaken using serological and molecular methods to detect HBsAg and specific IgM antibodies recognising core antigen HbcAg.

References
Liang TJ.2009. Hepatitis B: the virus and disease. Hepatology.May;49(5 Suppl): S13-21
Seeger C, Mason WS.2015. Molecular biology of hepatitis B virus infection. Virology.May;479-480:672-86.
World health Organization: Factsheet, Hepatitis B

Hepatitis B Antibodies

At The Native Antigen Company we offer a large panel of monoclonal antibodies specific to Hepatitis B. These antibodies recognise a number of different specific proteins, including the surface antigen, core antigen, and e antigen, all of which may be used in a wide range of applications to study the biology of Hepatitis B.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

4 + 11 =

Customer Feedback